

10/04/03

02527 U.S. PTO

**Utility
Patent Application
Transmittal**

(only for new non provisional applications under 37 CFR 1.53 (b))

Attorney Docket No.

PHMC0745-024

First Inventor

Bobrowski

Title

Topical Preparations for
Use in Treatment of
Anorectal Disease

Express Mail Label No.

EV 269354048 US

22278 U.S. PTO
10/678990

100403

APPLICATION ELEMENTS**ADDRESS TO:**Mail Stop Patent Application
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

1. ☐ Fee Transmittal Form
(submit an original and a duplicate)
2. ☒ Applicant Claims Small Entity status.
See 37 CFR 1.27
3. ☒ Specification (total pages 19)
(preferred arrangement set forth below)
- Descriptive title
 - Cross Reference to Related Applications
 - Statement Regarding Fed sponsored R&D
 - Reference to sequence listing
 - Background of the Invention
 - Brief Summary of the Invention
 - Brief Description of the Drawings
 - Detailed Description
 - Claim(s)
 - Abstract of the Disclosure
4. ☒ Drawing(s) (U.S.C. 113) [Total Sheets 5]
5. Oath or Declaration [Total Sheets 1]
- a. ☒ Newly executed original
- b. ☐ Copy from a prior application
- i. ☐ Deletion of Inventors
Signed statement attached deleting
inventor(s) name in prior application
6. ☐ Application Data Sheet

7. ☐ CD-Rom or CD-R in duplicate
8. Nucleotide and/or Amino Acid Sequence
(if applicable if necessary)
- a. ☐ Computer Readable Form
- b. Specification Sequence Listing On:
- i. ☐ CD-Rom or CD-R (2 copies); or
- ii. ☐ Paper
- c. ☐ Statements verifying identity of above copies

Accompanying Application Parts

9. ☒ Assignment Papers (cover sheet & document(s))
10. ☒ 37 CFR 3.73(b) Statement ☒ Power of Attorney
(when there is an assignee)
11. ☐ English Translation Document (if applicable)
12. ☐ Information Disclosure Statement
☐ Copies of IDS Citations
13. ☐ Preliminary Amendment
14. ☒ Return Receipt Postcard (MPEP 503)
(should be specifically itemized)
15. ☐ Certified Copy of Priority Document(s)
(if foreign priority is claimed)
16. ☐ Nonpublication Request under 35 U.S.C. 122(b)(2)
(B)(i) Applicant must attach form or equivalent
17. ☐ Other:

18. If a CONTINUING APPLICATION, check appropriate box, and supply the requisite information below and in the first sentence of the specification following the title, or in an Application Data Sheet under 37 CFR 1.76:

☐ Continuation ☐ Divisional ☐ Continuation-in-part (CIP) of prior application No.:

Prior application information:

Examiner _____

Art Unit: _____

For CONTINUATION OF DIVISIONAL APPS only; The entire disclosure of the prior application, from which an oath or declaration is supplied under Box 5b, is considered a part of the disclosure of the accompanying continuation or divisional application and is hereby incorporated by reference. This incorporation can only be relied upon when a portion has been inadvertently omitted from the submitted application parts.

19. CORRESPONDENCE ADDRESS

Customer Number

26948

or correspondence address below

Name					
Address					
City		State		Zip Code	
Country		Telephone		Fax	
Name	Michael F. Campillo			Registration No. (Attorney)	44583
Signature	<i>Michael F. Campillo</i>			Date	10/4/03

In re Application of: Bobrowski, Paul J.

Serial No.:

Examiner:

Filed: Oct. 04, 2003

Law Office:

Action Mailing Date:

Attorney Docket No.: PHMC0745-024

Title: Topical Preparations for Use in Treatment of Anorectal Disease


CERTIFICATE OF MAILING

I hereby certify that the following items are being deposited with the United States Postal Service as Express Mail (Post Office to Addressee), EV 269354048 US in an envelope addressed to: Mail Stop Patent Application, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on the date indicated below:

- Utility Patent Application Transmittal
- Declaration for Utility or Design Patent Application
- Power of Attorney and Correspondence Address Indication Form including statement under 37 CFR 3.73(b)
- Assignment Papers
- Specification (19 pages)
- Drawings (5 pages)
- Return Postcard
- Check No5907 for \$385.00

EV269354048US

Date: October 4, 2003


Michael F. Campillo